Revolutionizing Cardiovascular Treatments with the Use of AI: Current Status and Future Prospects

Katarzyna Szymańska MD¹, Katarzyna Szmyt MD¹, Julia Krasnoborska DMD²,

Sylwia Samojedny MD¹, Maciej Superson MD¹, Kamil Walczak MD¹,

Klaudia Wilk-Trytko MD¹, Julia Zarębska³, Tomasz Andrzej Duplaga⁴

¹University Clinical Hospital Fryderyk Chopin, Szopena 2, 35-055 Rzeszów, Poland

²Medicadent Clinic, Piątkowska 110A, 60-649 Poznań, Poland

³Medical University of Lublin, Aleje Racławickie 1, 20-059 Lublin, Poland

⁴Specjalistyczna Praktyka Stomatologiczna lek. stom. Andrzej Duplaga ul. Aleksandra Dworskiego 2, 37-700 Przemyśl, Poland
Katarzyna Szymańska, https://orcid.org/0009-0006-4473-3347, katarzyna2545@gmail.com
Katarzyna Szmyt, https://orcid.org/0000-0001-7883-0395, katarzynaszmyt1@gmail.com
Julia Krasnoborska, https://orcid.org/0000-0002-4541-0359, julia.kra@op.pl
Sylwia Samoedny, https://orcid.org/0009-0000-0302-4073, sylwiasamoedny@gmail.com
Maciej Superson, https://orcid.org/0000-0001-6891-9791, masuper987@gmail.com
Kamil Walczak, https://orcid.org/0009-0005-3136-846X, kamilwa987@gmail.com
Klaudia Wilk-Trytko, https://orcid.org/0009-0009-1507-0347, klaudiawilk.g11@gmail.com
Julia Zarębska, https://orcid.org/0009-0005-6861-6359, jzarebska2@gmail.com
Tomasz Andrzej Duplaga, https://orcid.org/0009-0007-4891-0539, tomaszduplaga6@gmail.com

Corresponding author: Katarzyna Szymańska; katarzyna2545@gmail.com

Abstract

**Introduction:** Artificial Intelligence (AI) has emerged as a seminal force in healthcare, fundamentally transforming various aspects of medical practice and patient care. This review explores the transformative impact of AI on the treatment of cardiovascular diseases (CVDs).

**State of Knowledge:** AI has revolutionized diagnostic accuracy, treatment precision, and patient management in the realm of cardiovascular care. It enhances diagnostic processes, enabling the early detection of CVDs through advanced imaging analysis and interpretation. Additionally, AI facilitates precision in risk stratification, identifying high-risk patient cohorts with heightened accuracy and informing personalized treatment strategies. Furthermore, AI optimizes drug selection and dosage regimens through pharmacogenomics, maximizing therapeutic efficacy while minimizing adverse drug reactions. Moreover, AI improves
precision and safety during interventional procedures, guiding clinicians in real-time decision-making and enhancing procedural outcomes.

**Conclusions:** AI is poised to revolutionize cardiovascular care, fostering innovation and improving patient outcomes.

**Keywords:** Artificial Intelligence, AI, Cardiovascular Diseases Treatment, Cardiovascular Diseases Diagnosis

1. **Introduction**

Cardiovascular diseases (CVDs) pose a significant global health challenge, representing a leading cause of morbidity and mortality worldwide. Despite remarkable advancements in medical science, the complexity and variability of cardiovascular conditions demand innovative solutions to enhance early detection, optimize treatment strategies, and mitigate risks associated with these diseases. Artificial intelligence (AI), with its capacity to analyze vast datasets, detect subtle patterns, and generate actionable insights, has emerged as a game-changer in cardiovascular care, from predictive analytics to image interpretation.

This review explores the current status and future prospects of revolutionizing cardiovascular treatments using AI. It examines the challenges in traditional approaches to cardiovascular care and the significant role of AI in addressing these challenges. Furthermore, it describes the opportunities and obstacles on the horizon, including technological advancements, regulatory considerations, and the imperative for collaborative efforts to harness the full potential of AI in cardiovascular medicine. The integration of AI promises to introduce a new era of precision medicine, where the treatment of CVDs is not only more
effective but also more personalized and accessible than ever before. By exploring the synergies between AI and cardiovascular care, this review delineates the path forward towards a future where the burden of CVDs is significantly alleviated, and the pursuit of cardiovascular health is empowered by the transformative capabilities of artificial intelligence.

2. Applications of AI in cardiovascular diseases treatment

2.1. AI in Diagnosing Cardiovascular Diseases: Enhancing Accuracy and Efficiency

AI is revolutionizing the diagnosis of CVDs, offering high sensitivity and specificity in interpreting diagnostic tests and imaging studies. One notable application of AI is in the interpretation of electrocardiograms (ECGs). AI-driven algorithms, such as the FDA-approved Kardia AI, analyze ECG data to detect arrhythmias, including atrial fibrillation (1). These algorithms can identify subtle abnormalities in ECG waveforms, enabling early detection of arrhythmias and facilitating timely intervention to prevent adverse cardiovascular events. Moreover, AI-powered echocardiography systems, such as the GE Healthcare Vivid E95, utilize deep learning algorithms to automate image analysis and quantify cardiac parameters, such as ejection fraction and ventricular volumes, with remarkable accuracy (2). By improving the echocardiographic workflow and reducing the dependence on manual measurements, AI-enhanced echocardiography systems enable clinicians to obtain rapid and consistent assessments of cardiac structure and function, aiding in the diagnosis of various cardiac conditions, including heart failure and valvular heart disease.

Additionally, AI is transforming cardiac imaging modalities, such as cardiac magnetic resonance imaging (MRI) and computed tomography (CT), by improving image quality, reducing artifacts, and assisting in the detection of coronary artery disease, myocardial infarction, and other structural abnormalities (3). For example, AI-powered image reconstruction algorithms, such as deep learning-based iterative reconstruction, enable the generation of high-resolution cardiac MRI images from limited raw data, reducing scan times and improving patient comfort (4). Similarly, AI-driven image analysis tools can automatically segment cardiac structures, detect pathological features, and quantify disease severity, providing valuable diagnostic information to clinicians (5). Using the diagnostic capabilities of AI, clinicians can accelerate the diagnostic process, improve diagnostic
accuracy, and enhance patient outcomes in cardiovascular care, leading to more effective management of cardiovascular diseases and better overall patient care.

2.2. Precision Risk Stratification: Identifying High-Risk Patient Cohorts

Precision risk stratification enable clinicians to identify individuals at heightened risk of cardiovascular events with high accuracy. Combining the abilities of AI and advanced analytics, precision risk stratification algorithms analyze vast datasets include clinical, genetic, lifestyle, and environmental factors to recognize subtle patterns and biomarkers indicative of increased cardiovascular risk. They integrate diverse sources of data, including electronic health records, medical imaging studies, genetic profiles, lifestyle habits, and environmental exposures, to construct extensive risk profiles for individual patients (6). Through multimodal analysis, these algorithms identify interactions and latent risk factors that may avoid traditional risk assessment models, enabling a more holistic understanding of each patient's cardiovascular risk profile.

Machine learning techniques, such as supervised learning, unsupervised learning, and deep learning enable predictive modeling of cardiovascular risk based on complex data patterns. Machine learning algorithms, such as random forest, support vector machines, and neural networks, underpin many precision risk stratification models, enabling the development of predictive models with high discriminatory power and generalizability. For instance, the Pooled Cohort Equations Risk Calculator, endorsed by the American College of Cardiology and the American Heart Association, employs machine learning techniques to estimate an individual's 10-year risk of developing atherosclerotic cardiovascular disease based on age, sex, race, cholesterol levels, blood pressure, diabetes status, and smoking history (7).

Moreover, precision risk stratification algorithms have the potential to uncover novel biomarkers and risk factors that may not be captured by traditional risk assessment tools. By analyzing high-dimensional data and using advanced feature selection techniques, AI algorithms can identify novel biomarkers indicative of early-stage disease processes, subclinical atherosclerosis, or genetic predispositions to cardiovascular conditions (8). Recent studies have demonstrated the utility of circulating biomarkers, such as high-sensitivity C-reactive protein (hs-CRP), lipoprotein(a) [Lp(a)], and genetic variants associated with lipid metabolism and inflammation, in refining cardiovascular risk prediction models (9).
incorporating these novel biomarkers into risk prediction algorithms, clinicians can enhance risk stratification accuracy and identify individuals at heightened risk of cardiovascular events.

2.3. Pharmacogenomics: Optimizing Drug Selection and Dosage

Pharmacogenomics represents a prime example of personalized medicine in cardiovascular care. Using pharmacogenomic data, clinicians can optimize drug selection and dosage regimens to maximize therapeutic efficacy while minimizing the risk of adverse drug reactions. For example, genetic variations in genes encoding drug-metabolizing enzymes, such as cytochrome P450 enzymes, can influence an individual's ability to metabolize certain medications, leading to variability in drug response (10). In the context of cardiovascular medicine, pharmacogenomic testing may inform the selection of anticoagulant therapies, such as warfarin or direct oral anticoagulants, based on an individual's genotype for enzymes involved in vitamin K metabolism or drug clearance (11). Similarly, genetic variants associated with drug targets, such as beta-adrenergic receptors for beta-blockers or ion channels for antiarrhythmic drugs, can inform personalized treatment strategies adjusted to an individual's genetic profile (12). Additionally, pharmacogenomic testing may guide dose adjustments for medications with narrow therapeutic indices, such as antiplatelet agents or antiarrhythmics, to optimize therapeutic outcomes while minimizing the risk of adverse drug events. By integrating pharmacogenomic information with clinical data and drug databases, clinicians can prescribe medications with greater precision, minimizing the risk of adverse drug reactions and optimizing therapeutic outcomes for patients with cardiovascular diseases.

While pharmacogenomics holds promise in optimizing drug selection and dosage in cardiovascular care, its integration into clinical practice faces several challenges. These challenges include the need for standardized testing protocols, clinician education and training on interpreting genetic test results, and cost-effectiveness considerations.

2.4. Interventional Guidance: Enhancing Precision in Cardiovascular Procedures

Modern AI-driven algorithms offer real-time guidance during interventional procedures, providing clinicians with invaluable insights at the point of care. For instance, in percutaneous coronary interventions (PCIs), AI algorithms analyze pre-procedural imaging data to accurately delineate coronary anatomy, identify lesion characteristics, and assess vessel patency, guiding precise stent placement and optimizing procedural success rates (13). Similarly, in transcatheter aortic valve replacements (TAVRs), AI-guided imaging analysis
facilitates precise valve sizing, annular assessment, and procedural planning, thereby reducing the risk of complications and improving patient outcomes (14). By using the power of AI-driven interventional guidance systems, clinicians can navigate anatomical structures, improve procedural workflows, and deliver precision-based care to patients undergoing cardiovascular interventions. This integration of AI technologies not only enhances procedural safety and efficacy but also raising the standard of care for patients with CVDs.

The evolution of interventional guidance extends beyond static imaging analysis to dynamic real-time decision support systems that enhance procedural precision and efficiency. For instance, the SYNTAX score, a widely-used tool for assessing the complexity of coronary artery disease, has been augmented by AI algorithms to provide instant risk stratification during PCIs (15). These algorithms integrate angiographic data with clinical variables to guide clinicians in selecting optimal treatment strategies and predicting procedural outcomes. Furthermore, AI-driven catheter navigation systems, such as the CorPath GRX System, enable precise robotic-assisted interventions, enhancing operator control and minimizing radiation exposure (16). In the realm of structural heart interventions, the use of AI-powered echocardiography guidance systems, such as the Philips EchoNavigator, facilitates real-time imaging fusion and catheter navigation, allowing for accurate device placement and immediate assessment of procedural success (17). By integrating AI-driven decision support tools into interventional workflows, clinicians can make informed decisions in real time and optimize procedural outcomes.

2.5. Remote patient monitoring and telemedicine

Remote patient monitoring (RPM) and telemedicine have emerged as integral components of modern cardiovascular care, using advancements in digital health technologies to improve patient management and clinical decision-making. RPM includes the continuous collection and transmission of patient data, including vital signs, ECG, activity levels, and medication adherence, through wearable sensors, mobile apps, and remote monitoring platforms (18). For instance, wearable devices such as smartwatches equipped with photoplethysmography (PPG) sensors can provide real-time monitoring of heart rate variability, enabling early detection of arrhythmias and cardiac abnormalities (19). Similarly, implantable cardiac devices like pacemakers and implantable cardioverter-defibrillators (ICDs)
offer remote monitoring capabilities, transmitting data on device function, arrhythmia episodes, and patient activity to doctors for proactive management (20).

Telemedicine, on the other hand, facilitates the delivery of cardiovascular care through virtual consultations, telemonitoring, and tele-rehabilitation, overcoming geographical barriers and expanding access to specialized services. For example, telecardiology programs enable cardiologists to remotely review ECGs, echocardiograms, and other diagnostic images, providing timely interpretations and recommendations to primary care physicians or patients directly (21). Teleconsultations allow patients to discuss symptoms, review treatment plans, and receive medical advice from cardiovascular specialists without the need for in-person visits, reducing travel burdens and enhancing patient convenience. Moreover, telemedicine platforms can support remote cardiac rehabilitation programs, delivering exercise prescriptions, education modules, and behavioral interventions to patients recovering from acute cardiac events or managing chronic cardiovascular conditions (22).

By integrating RPM and telemedicine into routine clinical practice, healthcare providers can proactively monitor patients with chronic cardiovascular conditions, identify early signs of decompensation or disease progression, and intervene promptly to prevent adverse outcomes. For instance, remote monitoring of blood pressure, weight, and fluid status in patients with heart failure enables early detection of volume overload or worsening symptoms, prompting adjustments in medication dosages or lifestyle modifications to prevent hospitalizations (23). Similarly, telemedicine-enabled cardiac rehabilitation programs have been shown to improve adherence to exercise regimens, reduce hospital readmissions, and enhance quality of life in patients recovering from myocardial infarction or cardiac surgery (24).

3. Future prospects and challenges

3.1. Advancements in AI technology and algorithms

Advancements in AI technology and algorithms are rapidly transforming the area of cardiovascular care. One of such innovation is the development of deep learning architectures, including convolutional neural networks (CNNs) and recurrent neural networks (RNNs), which have demonstrated remarkable capabilities in analyzing complex medical imaging data (25,26). For instance, CNN-based algorithms can automatically detect and classify abnormalities in cardiac MRI and CT scans with high accuracy, facilitating early diagnosis of
conditions such as coronary artery disease, myocardial infarction, and structural heart defects (27). Similarly, RNNs equipped with long short-term memory (LSTM) units enable the analysis of temporal patterns in physiological signals, such as ECGs and continuous blood pressure readings, for real-time monitoring of cardiovascular function and early detection of arrhythmias or hemodynamic instability (28).

Furthermore, advancements in natural language processing (NLP) techniques are enabling AI-driven analysis of unstructured clinical notes, electronic health records, and medical literature to extract meaningful insights and inform clinical decision-making in cardiovascular medicine. For example, NLP algorithms can automatically analyze and summarize patient histories, laboratory results, and medication lists, aiding clinicians in risk stratification, treatment planning, and care coordination (29). Moreover, the integration of knowledge graphs and semantic representations into NLP models enables the contextual understanding of cardiovascular concepts and facilitates the synthesis of different sources of information to support evidence-based practice and clinical research.

In addition to these algorithmic advancements, the convergence of AI with other cutting-edge technologies, such as federated learning, blockchain, and edge computing, holds promise for addressing key challenges in cardiovascular care, including data privacy, security, and scalability. Federated learning frameworks allow AI models to be trained collaboratively across distributed healthcare institutions while preserving data privacy and security, enabling the development of robust and generalizable algorithms on heterogeneous patient populations. Similarly, blockchain-based platforms offer secure and constant storage of medical data, facilitating transparent and controlled transactions for data sharing, consent management, and interoperability in cardiovascular research and healthcare delivery (30).

3.2. Integration of AI with other emerging technologies

The integration of AI with other emerging technologies represents a milestone in advancing cardiovascular care, offering synergistic opportunities to enhance diagnosis, treatment, and patient outcomes. One such area of integration is the convergence of AI with genomics and precision medicine approaches, enabling the understanding of genetic risk factors, molecular pathways, and therapeutic targets for cardiovascular diseases (31). AI-driven algorithms can analyze genomic datasets to identify genetic variants associated with susceptibility to conditions such as coronary artery disease, hypertension, and
cardiomyopathies, facilitating personalized risk assessment and treatment selection based on individual genetic profiles. Moreover, AI-powered predictive modeling techniques can integrate genomic, clinical, and environmental data to stratify patients into distinct subgroups with differing disease trajectories and response to therapy.

Furthermore, the integration of AI with Internet of Things (IoT) technologies holds promise for remote monitoring, early detection, and intervention in cardiovascular conditions through connected devices and sensors. IoT-enabled wearable devices, such as smartwatches, patches, and implantable sensors, can continuously collect and transmit physiological data to AI-driven analytics platforms for real-time monitoring and analysis. For example, AI algorithms can detect subtle changes in heart rate variability, oxygen saturation, or electrocardiographic patterns indicative of arrhythmias, ischemia, or heart failure exacerbations, triggering alerts and interventions to prevent adverse events and improve patient outcomes (32,33). Moreover, the integration of IoT-enabled devices with AI-powered telemedicine platforms enables remote consultations, virtual cardiac rehabilitation programs, and personalized health coaching, extending access to cardiovascular care beyond traditional healthcare settings and empowering patients to actively engage in self-management and disease prevention efforts.

Additionally, the integration of AI with robotics and minimally invasive technologies holds promise for enhancing the precision, safety, and efficacy of interventional procedures in cardiovascular medicine. AI-driven robotic systems can assist cardiologists and cardiac surgeons in performing complex interventions, such as PCIs, TAVRs, and arrhythmia ablations, with greater accuracy and efficiency, reducing procedural risks and improving patient outcomes (34). Moreover, AI algorithms can analyze intraoperative imaging data, such as fluoroscopy, intracardiac echocardiography (ICE) and optical coherence tomography (OCT), to guide catheter navigation, optimize device placement, and assess treatment efficacy in real time (35,36). Furthermore, the integration of AI-driven predictive modeling techniques with robotics and imaging technologies enables the development of patient-specific treatment plans, simulation-based training programs, and risk stratification algorithms to optimize procedural outcomes and minimize complications in cardiovascular interventions.
3.3. Regulatory and ethical considerations

Navigating the regulatory and ethical landscape surrounding the integration of AI into cardiovascular care demands special attention to detail and adherence to established principles. Regulatory agencies, such as the Food and Drug Administration (FDA) in the United States and the European Medicines Agency (EMA) in Europe, play crucial roles in ensuring the safety, efficacy, and quality of AI-driven medical devices and algorithms. Robust regulatory frameworks must be established to evaluate the performance, reliability, and generalizability of AI algorithms across diverse patient populations and clinical settings. This necessitates rigorous validation studies, adherence to quality standards, and transparent reporting of algorithm performance metrics, including sensitivity, specificity, positive predictive value, and area under the receiver operating characteristic curve (AUC-ROC) (37). Furthermore, regulatory oversight should extend to data privacy and security, ensuring compliance with regulations such as the Health Insurance Portability and Accountability Act and the General Data Protection Regulation to protect patient confidentiality and prevent unauthorized access or misuse of health data.

Ethical considerations surrounding AI in cardiovascular care includes a wide range of issues, such as algorithm bias, fairness, transparency, and accountability. AI algorithms trained on biased or incomplete datasets may perpetuate disparities in healthcare access, diagnosis, and treatment outcomes, particularly among underserved or marginalized populations. To address this, efforts should be made to ensure diversity and representativeness in training data and to implement algorithmic fairness metrics and bias mitigation strategies to mitigate unintended biases and promote equitable healthcare delivery. Moreover, transparency and explainability are essential for trust promotion and accountability in AI-driven decision-making processes, enabling clinicians and patients to understand how algorithms arrive at recommendations and facilitating informed consent and shared decision-making. Additionally, mechanisms for algorithmic accountability, such as post-market surveillance, auditability, and recourse mechanisms for patients, are essential to monitor algorithm performance, detect errors or biases, and rectify adverse consequences in a timely and transparent manner.

4. Conclusion

The applications of AI in CVDs treatment span a wide spectrum of areas, from enhancing diagnostic accuracy and efficiency to enabling precision risk stratification, optimizing drug
selection and dosage through pharmacogenomics, and guiding interventional procedures with unprecedented precision. AI-driven innovations hold promise in revolutionizing the area of cardiovascular care, empowering clinicians with data-driven insights, and improving patient outcomes. However, alongside these opportunities, significant challenges must be addressed, including regulatory considerations, ethical concerns, and the integration of AI with other emerging technologies. Regulatory agencies and policymakers must establish robust frameworks to ensure the safety, efficacy, and privacy of AI-driven technologies while fostering innovation and accessibility. Ethical considerations surrounding algorithm bias, transparency, and accountability demand thoughtful deliberation and prudent governance to uphold principles of fairness, equity, and patient welfare. Moreover, the integration of AI with other emerging technologies, such as genomics, IoT, and robotics, presents synergistic opportunities to advance cardiovascular care but requires interdisciplinary collaboration and careful coordination to maximize benefits and mitigate risks.

Authors contribution

Conceptualization: Katarzyna Szymańska; Methodology: Sylwia Samojedny; Validation: Katarzyna Szymańska, Kamil Walczak, Tomasz Andrzej Duplaga; Formal analysis: Katarzyna Szymańska; Katarzyna Szmyt, Maciej Superson; Investigation: Julia Krasnoborska, Klaudia Wilk-Trytko, Katarzyna Szmyt; Maciej Superson, Julia Zarębska; Resources: Sylwia Samojedny; Katarzyna Szymańska; Writing-Original Draft Preparation: Katarzyna Szymańska, Maciej Superson, Katarzyna Szmyt, Klaudia Wilk-Trytko, Julia Zarębska, Tomasz Andrzej Duplaga; Writing - Review & Editing: Kamil Walczak, Julia Krasnoborska, Katarzyna Szymańska.

All authors have read and agreed with the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.
Conflicts of Interest
The authors declare no conflict of interest.

References:


